Claude Knopf

Claude Knopf has extensive work experience in the biotech and pharmaceutical industries. Claude is currently serving as the Chief Business Officer at Imcheck Therapeutics since June 2020. Prior to this, they took a sabbatical from January 2019 to June 2020 as the Chief Business Officer on Adoption Sabbatical. Before that, they worked as the Chief Business Officer at Gemini Therapeutics from April 2018 to June 2020. Claude also held the position of Chief Business Officer at Pieris Pharmaceuticals from November 2016 to December 2017.

Their previous roles include being the Senior Vice President, Global Head of Business Development & Licensing, and Mergers & Acquisitions at Baxalta - Baxter Bioscience from July 2013 to July 2016. Prior to that, they worked at Novartis Vaccines and Diagnostics, where they held various positions including Head of Business Development & Licensing and Strategic Planning for the European region from June 2010 to June 2013, and Head of Business Development for The Americas Consumer Health from January 2009 to June 2010.

Claude also had a successful tenure at Novartis, where they served as the Head of Business Development & Licensing for the European region from 2005 to 2008, and as the Head of Alliance Management for the Global Resp/Derm Franchise from 2002 to 2005.

Before entering the biotech and pharmaceutical field, Claude worked at Merck as a Brand Manager and Sales Representative for Vasotec and Zocor, and later as a Senior Internal Audit Manager from June 1995 to March 1997. Claude started their career at Valeo as the Financial Director of a plant in Turkey from January 1993 to June 1995.

Claude Knopf has an extensive education history. Claude started their education at Université Louis Pasteur in 1987 and earned a DEUG degree in economics in 1989. Claude then went on to study at Manchester University, where they obtained a Bachelor of Arts degree with honors in economics from 1989 to 1991. Claude later pursued an International MBA (MIBS) from Darla Moore School of Business, completing it from 1991 to 1993. In 2009, Claude attended Harvard Business School for an executive education program focused on 3-D Negotiations. In 2012, they furthered their education at Tufts University, taking a post-graduate course in clinical development. That same year, Claude also attended The Wharton School for a mergers and acquisitions executive education program.